Fundz
You are reading one round. Fundz also knows which of your own LinkedIn connections can open this account.See it live →

Sling Therapeutics, Inc. closes $123 million Series C financing led by Forbion to advance Phase 3 development of its oral small molecule IGF-1R inhibitor for thyroid eye disease.

PRIVATESep 16, 2026•about 3 hours ago

Amount Raised

$123 Million

Round Type

Series C

Ann ArborHealth Care

Investors

Sectoral Asset ManagementTpg Life Sciences InnovationsForbion

Description

Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company, has closed a $123 million Series C financing. The financing was led by Forbion with participation from existing investor TPG Life Sciences Innovations and new investor Sectoral Asset Management. Proceeds will support the continued clinical advancement of their therapy for thyroid eye disease.

Company Information

Company

Sling Therapeutics

Location

Ann Arbor, Michigan, United States

About

The company is also exploring additional potential indications beyond TED, including in rare and autoimmune diseases. The company is advancing the evaluation of its lead product candidate, linsitinib, in a Phase 2b clinical trial based on extensive preclinical and clinical data. Sling Therapeutics, Inc., is a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED).

Don't miss Sling Therapeutics's next move

Get an email the moment Sling Therapeutics raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Sling Therapeutics's next move

See what Strategic adds

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Sling Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.